• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • PERFADEX® Plus
    • XVIVO
      Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
    • Movies
  • Media
    • Videos
    • Webinars
  • About us
    • About Xvivo
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO Perfusion
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Thank you
    • Error
XVIVO Perfusion
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • Steen Solution™
    • PERFADEX® Plus
    • XVIVO
      Silicone Tubing Set™
    • XVIVO LS™ & XVIVO Disposable Lung Set™
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
    • Movies
  • Media
    • Videos
    • Webinars
  • About us
    • About Xvivo
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO Perfusion
  • Corporate
    • Corporate
    • The share
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • CODE OF CONDUCT
    • Privacy policy
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
  • Press releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • CODE OF CONDUCT
  • Privacy policy
  • Subscribe
  • Thank you
  • Error

Report on operations 2015

Strong sales growth and increased EBITDA

FOURTH QUARTER 2015 (OCT – DEC)

• Net sales in the quarter amounted to SEK 32.7 (25.5) million, corresponding to an increase of 28 percent. Net sales increased by 17 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 6.9 (3.1) million, corresponding to an EBITDA margin of 21 percent.
• Net income amounted to SEK 2.8 (0.3) million, resulting in earnings per share of SEK 0.13 (0.01). The figures are affected by amortization and depreciation of SEK 3.1 (2.6) million.
• Cash flow from operating activities was SEK 2.9 (-5.4) million.
• Net sales of non-Durable goods* in the quarter amounted to SEK 29.1 (25.5) million, corresponding to an increase of 14 percent in SEK. Sales of non-Durable goods increased by 5 percent in local currency.
• Products for warm perfusion (STEEN Solution™, the XPS™ and products related to the use of the XPS™) accounted for 40 (34) percent of total product sales.
• Three XPS™ was delivered during the quarter. One to the US and two to Europe, whereof one to the world’s second largest lung transplant clinic in Vienna, Austria.
• The China Food and Drug Administration (CFDA) approved STEEN Solution™ for marketing and clinical use in China.

THE PERIOD 2015 (JAN – DEC)

• Net sales in the period amounted to SEK 120.2 (84.7) million, corresponding to an increase of 42 percent. Net sales increased by 25 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 18.8 (11.4) million, corresponding to an EBITDA margin of 16 percent.
• Net income amounted to SEK 5.1 (5.2) million, resulting in earnings per share of SEK 0.24 (0.25) after depreciation and amortization of SEK 11.6 (3.9) million had been charged to the period.
• Cash flow from operating activities was SEK 8.6 (-4.6) million.
• Net sales of non-Durable goods* in the period amounted to SEK 106.0 (83.2) million, corresponding to an increase of 27 percent in SEK. Sales of non-Durable goods increased by 12 percent in local currency.
• Products for warm perfusion (STEEN Solution™, the XPS™ and products related to use of the XPS™) accounted for 39 (28) percent of total product sales.
• The first XPS™ was delivered to Europe. During the year a total of 4 clinics in Europe gained access to the XPS™, including the world’s second largest lung transplant clinic in Vienna, Austria.
• The United States Patent and Trademark Office approved a third patent in the “Preservation and evaluation solution” family, which means that STEEN Solution™ and the XPS™ have broader patent protection in the US.
• A strategic decision was made to apply for listing on Nasdaq Stockholm’s main market during 2016.
• The first liver transplant using STEEN Solution™ was performed in Toronto, Canada, as part of a clinical phase 1 study.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• A decision was made to apply for listing on the First North Premier segment as one step on the way to preparing the company for an application for listing on NASDAQ Stockholm’s main market.
• The company has obtained a CE mark for a patent-protected product, PrimECC®, which has been developed to prime heart-lung machines before open heart surgery. The company will expand the clinical documentation for PrimECC® through more clinical studies in 2016.
• At the time of publication of this report, 23 clinics have access to the XPS™, including 18 clinics in the US and 4 clinics in Europe.
• After the end of the quarter one XPS™ contract was signed in Europe

CONFERENCE CALL

 CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, February 4, 2016. Telephone: +44 (0) 1452 555566, enter code 68991296.

February 4, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Durable goods are sales revenues from the XPS™.

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com

For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on February 4, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About us

XVIVO Perfusion is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivoperfusion.com

Newsletter

I have read and accepted XVIVO Perfusion's Privacy Policy

*By signing up to our newsletter you consent to XVIVO Perfusion sending you our insights newsletter and occasional additional communications. Your personal data will be transfered to a third party newsletter distributor engaged by XVIVO Perfusion. All processing of your personal data is in compliance with the XVIVO Perfusion Privacy Policy. For more information on how we use your personal data, please read XVIVO Perfusion’s Privacy policy

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2021 XVIVO Perfusion. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO Perfusion. Read more about Cookies

Approve